Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of pregabalin as compared to
placebo in the treatment of patients with general anxiety disorder (GAD). Efficacy will be
measured by the improvement in the total Hamilton Anxiety Rating Scale (HAM-A) scores from
baseline observed following 8 weeks of double-blind treatment or at earlier termination
during the double-blind treatment phase and analyzed using a mixed linear model for repeated
measures.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.